C4 Therapeutics (CCCC) Non Operating Income (2019 - 2026)

C4 Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 6.54% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 24.23% decrease from a year earlier, with the FY2025 full-year figure at $10.3 million, down 28.28% from the prior year.
• Non Operating Income slipped to $2.7 million in Q1 2026 per CCCC's latest filing, from $2.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.9 million in Q1 2024 and bottomed at -$251000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.5 million (2025), against an average of $2.2 million.
• Across the five-year window, Non Operating Income soared 5978.57% in 2023 and sank 37.23% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.1 million in 2022, then surged by 166.25% to $2.9 million in 2023, then increased by 10.75% to $3.3 million in 2024, then dropped by 14.91% to $2.8 million in 2025, then fell by 4.46% to $2.7 million in 2026.
• Per Business Quant, the three latest CCCC Non Operating Income figures stand at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.2 million (Q3 2025).